Clinical Trials Browser

Phase 1 × Myeloproliferative Disorders × Idarubicin × Clear all

NCT06034470 2026-02-20

Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases

NCT02029950 2020-10-14

Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Phase 1 Completed

50 enrolled

MyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT00331513 2013-09-30

Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes

Phase 1 Completed

40 enrolled

LymphoidMyeloidOther hematologic neoplasm

Congenital Abnormalities, Blast Crisis, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Promyelocytic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma